NCT04095936View on ClinicalTrials.gov

Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 3, 2019

Primary Completion Date

October 7, 2021

Study Completion Date

October 29, 2021

Conditions
Aplastic Anemia
Interventions
DRUG

Romiplostim

Subcutaneous administration of 0 to 20ug/kg for 6 months

Trial Locations (1)

Unknown

NTT Medical center Tokyo, Shinagawa

All Listed Sponsors
lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT04095936 - Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia | Biotech Hunter | Biotech Hunter